BillionToOne shares jump as much as 100% in stunning Nasdaq debut

Molecular diagnostics firm BillionToOne's BLLN.O shares jump as much as 100% in their Nasdaq debut

Stock opened at $100 apiece and jumped as high as $120; last up 93.6% at $116.15

BLLN sold 4.56 million shares in an upsized IPO at $60 apiece to raise $273.1 million

Menlo Park, California-based BLLN had initially marketed 3.85 million shares between $49 and $55 apiece

BLLN develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for various diseases

In the six months ended June 30, BLLN's revenue surged 82% to $125.5 million, while net loss narrowed to $4.2 million

J.P. Morgan, Piper Sandler, Jefferies and William Blair were joint book-running managers for the offering